bmj梁文华肺癌EGFRTKI_NMA_20191103_bmj.l5460.full参考.doc

bmj梁文华肺癌EGFRTKI_NMA_20191103_bmj.l5460.full参考.doc

  1. 1、本文档共16页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
R E S E A RC H Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis Yi Zhao,1 Jingting Liu,1 Xiuyu Cai,2 Zhenkui Pan,3 Jun Liu,1 Weiqiang Yin,1 Hanzhang Chen,1 Zhanhong Xie,4 Hengrui Liang,1 Wei Wang,1 Zhihua Guo,1 Shen Zhao,5 Wenhua Liang,1 Jianxing He1 For numbered affiliations see end of the article. Correspondence to: J He drjianxing.he@; (ORCID 0000-0003-1737-8192) Liang liangwh1987@163.com (ORCID 0000-0002-1391-8238) Additional material is published online only. To view please visit the journal online. Cite this as: BMJ 2019;367:l5460 /10.1136/bmj.l5460 Accepted: 21 August 2019  Abstract Objective To compare the efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). Design Systematic review and network meta-analysis. Data sources PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalT, and several international conference databases, from inception to 20 May 2019. Eligibility criteria for selecting studies Published and unpublished randomised controlled trials comparing two or more treatments in the first line setting for patients with advanced EGFR mutated NSCLC were included in a bayesian network meta-analysis. Eligible studies reported at least one of the following clinical outcome measures: progression free survival, overall survival, objective response rate, and adverse events of grade 3 or higher. Results 18 eligible trials involved 4628 patients and 12 treatments: EGFR tyrosine kinase inhibitors (TKIs;  osimertinib, dacomitinib, afatinib, erlotinib, gefitinib, and icotinib), pemetrexed based chemotherapy, pemetrexed free chemotherapy, and combination treatments (afatinib plus cetuximab, erlotinib plus bevacizumab, gefitinib plus pemetrexed based chemotherapy, and gefitinib plus pemetrexed). Consis

您可能关注的文档

文档评论(0)

陈小颜童鞋 + 关注
实名认证
内容提供者

要是文档已下架,仅可试读部分内容的,请私信我 本账号发布文档部分原创,部分来源于互联网和个人收集,仅用于技术分享交流,版权为原作者所有,如果侵犯了您的知识版权,请提出指正,将立即删除相关资料。

版权声明书
用户编号:7066016145000016

1亿VIP精品文档

相关文档